Analysis of Antidepressant-like Effects and Action Mechanisms of GSB-106, a Small Molecule, Affecting the TrkB Signaling
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Induction of BDNF-TrkB signaling is associated with the action mechanisms of conventional and fast-acting antidepressants. GSB-106, developed as a small dimeric dipeptide mimetic of BDNF, was previously shown to produce antidepressant-like effects in the mouse Porsolt test, tail suspension test, Nomura water wheel test, in the chronic social defeat stress model and in the inflammation-induced model of depression. In the present study, we evaluated the effect of chronic per os administration of GSB-106 to Balb/c mice under unpredictable chronic mild stress (UCMS). It was observed for the first time that long term GSB-106 treatment (1 mg/kg, 26 days) during ongoing UCMS procedure ameliorated the depressive-like behaviors in mice as indicated by the Porsolt test. In addition, chronic per os administration of GSB-106 resulted in an increase in BDNF levels, which were found to be decreased in the prefrontal cortex and hippocampus of mice after UCMS. Furthermore, prolonged GSB-106 treatment was accompanied by an increase in the content of pTrkB706/707 in the prefrontal cortex and by a pronounced increase in the level of pTrkB816 in both studied brain structures of mice subjected to UCMS procedure. In summary, the present data show that chronic GSB-106 treatment produces an antidepressant-like effect in the unpredictable chronic mild stress model, which is likely to be associated with the regulation of the BDNF-TrkB signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two BDNF mimickers currently under investigation are dipeptide N-monosuccinyl-L-seryl-L-lysine and 7,8-Dihydroxyflavone (187).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [187]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., & Hashimoto, K. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu121 · Cited by 103 · cited 1×
“It is well known that long-term exposure to stress, as well as other conditions that contribute to the depressive-like behavior in animals, is accompanied by a BDNF expression decrease in the prefrontal cortex and in the hippocampus, while an increase in the level of neurotrophin has been observed in the nucleus accum…”
BackgroundRetractedRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“However, the long onset time for antidepressants effects (several weeks to months), a significant number of patients that do not respond to typical antidepressants and a broad range of side effects significantly limit the efficacy of treatment [12].”
BackgroundThe Neuroendocrinology of Stress: A Never Ending Story
Lightman, S. L. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01711.x · Cited by 3,566
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375 · cited 5×
“It has been widely shown that chronic stress-induced behavioral changes are associated with neuronal atrophy and reduced levels of BDNF and phosphorylated/activated TrkB in the prefrontal cortex and the hippocampus in rodents, while almost all antidepressants can restore BDNF level and activate TrkB receptors in roden…”
BackgroundResultInfluentialNestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 2×
“Numerous basic research findings confirm that typical antidepressants increase the BDNF mRNA and protein expression as well as the TrkB activation in the hippocampus and the cortex [3,7,15], thus promoting the structural plastic changes associated with the antidepressant action mechanisms [8,16,17].”
BackgroundNibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 2×
“Numerous basic research findings confirm that typical antidepressants increase the BDNF mRNA and protein expression as well as the TrkB activation in the hippocampus and the cortex [3,7,15], thus promoting the structural plastic changes associated with the antidepressant action mechanisms [8,16,17].”
BackgroundWillner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795 · cited 1×
“Numerous basic research findings confirm that typical antidepressants increase the BDNF mRNA and protein expression as well as the TrkB activation in the hippocampus and the cortex [3,7,15], thus promoting the structural plastic changes associated with the antidepressant action mechanisms [8,16,17].”
BackgroundSustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780
Cited by
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“Two BDNF mimickers currently under investigation are dipeptide N-monosuccinyl-L-seryl-L-lysine and 7,8-Dihydroxyflavone (187).”
BackgroundStress-Induced Depression and Alzheimer’s Disease: Focus on Astrocytes
Dolotov, O. V., Inozemtseva, L. S., Myasoedov, N. F., & Grivennikov, I. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094999 · Cited by 110
“Another promising approach, in our opinion, is associated with the use of short peptide mimetics of BDNF, which are able to activate TrkB receptors demonstrating a pronounced antidepressant effects [210].”
BackgroundNeurotrophin-targeted therapeutics: A gateway to cognition and more?
Nordvall, G., Forsell, P., & Sandin, J. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.07.003 · Cited by 48
Stimulating myelin restoration with BDNF: a promising therapeutic approach for Alzheimer's disease
Zota, I., Chanoumidou, K., Gravanis, A., & Charalampopoulos, I. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1422130 · Cited by 26
Charou, D., Rogdakis, T., Latorrata, A., Valcárcel, M., Papadogiannis, V., Athanasiou, C., Tsengenes, A., Papadopoulou, M. A., Lypitkas, D., Lavigne, M. D., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03818-w · Cited by 18
Межлумян, А. Г., Таллерова, А. В., Povarnina, P. Y., Тарасюк, А. В., Sazonova, N. M., Гудашева, Т. А., & Середенин, С. Б. (2022) · Pharmaceuticals · doi:10.3390/ph15030284 · Cited by 16
“The antidepressant-like effects of GSB-106 were shown not only in behavioral despair tests, but also in social defeat stress and chronic unpredictable stress models in rodents [32,33].”
BackgroundГудашева, Т. А., Povarnina, P. Y., Антипова, Т. А., Логвинов, И. О., & Середенин, С. Б. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230103161824 · Cited by 12
Sigma-1 Receptor Ligands for CNS Cancer Treatment
Prasansuklab, A., Safrany, S. T., Brimson, S., & Brimson, J. M. (2025) · CNS Drugs · doi:10.1007/s40263-025-01223-2 · Cited by 10
Exploring combat stress exposure effects on burn pain in a female rodent model
Strain, M. M., Tongkhuya, S. A., Wienandt, N., Alsadoon, F., Chavez, R., Daniels, J., Garza, T. H., Trevino, A. V., Wells, K., Stark, T. R., et al. (2022) · BMC Neuroscience · doi:10.1186/s12868-022-00759-z · Cited by 4
“Additionally, activation of BDNF-TrkB signaling is one mechanism of action for conventional and fast-acting antidepressants [52].”
BackgroundАнтипова, Т. А., Логвинов, И. О., Deyev, I. E., Povarnina, P. Y., Vakhitova, Y. V., Гудашева, Т. А., & Середенин, С. Б. (2023) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672923700230 · Cited by 3
“GSB-106 systemically administered at doses of 0.1–1.0 mg/kg showed antidepressant-like activity in standard experimental models [13, 16, 17], which, as was shown by pharmacological inhibitor assay, is mediated by activation of TrkB and associated signal transduction pathways [16].”
BackgroundInfluentialSelf-citationYan, Z., Yu, J., Wang, S., Wen, W., Xin, M., & Li, X. (2024) · Discover Oncology · doi:10.1007/s12672-024-01271-y · Cited by 3
Raswanthiya, S. P., Fernandes, O. P., Mathew, M. P., Balgote, P. J., & Sivaraman, J. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11485-8 · Cited by 5
“Other promising approaches include peptidomimetics such as GSB-106 and synthetic neuro-steroids like BNN-20, which may mimic endogenous neurotrophic factors and enhance the resilience of dopaminergic neurons [125].”
Антипова, Т. А., Логвинов, И. О., Deyev, I. E., Povarnina, P. Y., Vakhitova, Y. V., Гудашева, Т. А., & Середенин, С. Б. (2023) · Доклады Российской академии наук Науки о жизни · doi:10.31857/s2686738923600218 · Cited by 2
Self-citationГудашева, Т. А., Povarnina, P. Y., Тарасюк, А. В., Жердев, В. П., & Дурнев, А. Д. (2025) · Pharmacokinetics and Pharmacodynamics · doi:10.37489/2587-7836-2024-4-3-16 · Cited by 2
Charou, D., Rogdakis, T., Latorrata, A., Valcárcel, M., Papadogiannis, V., Athanasiou, C., Tsengenes, A., Papadopoulou, M. A., Lypitkas, D., Lavigne, M. D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.08.539797
Kayser, J. M., Petry, F., Souza, M. A., Schindler, M. S. Z., Morgan, L. V., Rodrigues, G. Z. P., Mazon, S. C., Aguiar, G. P. S., Pitta, M. G. D. R., Pitta, I. D. R., et al. (2024) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000785 · Cited by 2
“…that the effect of antidepressant treat-ment on BDNF levels is considered a time-dependent response that normally requires a long-term treatment for physical growth and reorganization of the brain (Molteni et al ., 2006; Donnici et al ., 2008; Castrén and Rantamäki, 2010; Vakhitova et al ., 2021).”
Pharmacodynamics of Drugs Adaptation to Activity in Extreme Conditions
Vakhitova, Y. V. (2024) · Human Physiology · doi:10.31857/s0131164624040138
Self-citationSazonova, N. M., Тарасюк, А. В., Filippova, M. Y., Melnikova, M. V., Никифоров, Д. М., Povarnina, P. Y., Гудашева, Т. А., & Дорофеев, В. Л. (2024) · Pharmacokinetics and Pharmacodynamics · doi:10.37489/2587-7836-2024-3-25-37
Pharmacodynamics of the Adaptation of Drugs to Activity in Extreme Conditions
Vakhitova, Y. V. (2024) · Human Physiology · doi:10.1134/s0362119724700890
“3 [30]).”
InfluentialSelf-citationAdditional file 1 of Exploring combat stress exposure effects on burn pain in a female rodent model
Strain, M. M., Tongkhuya, S. A., Wienandt, N., Alsadoon, F., Chavez, R., Daniels, J., Garza, T. H., Trevino, A. V., Wells, K., Stark, T. R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.22601326
Gagliano, C., Avitabile, A., & Rusciano, D. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl46738
Metadata
- Authors
- Vakhitova, Y. V., Kalinina, T. S., Zainullina, L. F., Lusta, A. Y., Volkova, A. V., Kudryashov, N. V., Gudasheva, T. A., Shimshirt, A. A., Kadnikov, I. A., Voronin, M. V., & Seredenin, S. B.
- Affiliations
- Institute of Pharmacology Russian Academy of Medical Sciences (RU)
- Department of Psychopharmacology, FSBI “Zakusov Institute of Pharmacology”, Baltiyskaya Street 8, 125315 Moscow, Russia
- Department of Pharmacogenetics, FSBI “Zakusov Institute of Pharmacology”, Baltiyskaya Street 8, 125315 Moscow, Russia
- Department of Medicinal Chemistry, FSBI “Zakusov Institute of Pharmacology”, Baltiyskaya Street 8, 125315 Moscow, Russia
- Corresponding author
- Vakhitova, Yulia V.
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-12-13
- Volume
- 22
- Issue
- 24
- Pages
- 13381
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8704497
- OpenAlex
- W4200538075
- Cited by
- 21
- References
- 88
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 7 · 2023: 5 · 2022: 5
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Science and Higher Education of the Russian Federation (Project 0521-2019-0002)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- antidepressant-like effects, BDNF/TrkB signaling, TrkB phosphorylation, BDNF mimetic, chronic unpredictable mild stress, depression, prefrontal cortex, hippocampus, rapid-acting antidepressants
- MeSH terms
- Animals, Antidepressive Agents, Brain, Dipeptides, Hippocampus, Male, Membrane Glycoproteins, Mice, Inbred BALB C, Protein-Tyrosine Kinases, Stress, Psychological, Signal Transduction, Prefrontal Cortex, Brain-Derived Neurotrophic Factor, Receptor, trkB, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.